Kirkeveien 166, Frederik Holsts hus (map)
New paper in Gastroenterology: Authors found that both aspirin, and in particular oral anticoagulants, lowers the positive predictive value of fecal testing for occult blood.
One of the major concerns of cancer screening is interval cancers, which are cancers arising after a negative screening test. These cancers have been believed to be especially aggressive and have a poor prognosis. A new study shows that they are not.
Standardized computer-aided diagnosis (CAD) can help reduce unnecessary removal of colonic polyps with no malignant potential.
Overdiagnosis is recognized as a major harm of mammography and prostate cancer screening – what about colorectal cancer screening?
Professor Michael Bretthauer was the first gastroenterologist to be teleported into a patient's colon in a shrunked version of himself, only to get a better view of the colonic polyps. The sensational event took place during the Felix Burda Award in Berlin this weekend.
A paper published today in BMJ shows no effect of sigmoidoscopy screening in women aged 60 years and older. This new finding will have implications for a future Norwegian colorectal cancer screening program, where sigmoidoscopy is one of the recommended screening methods.
A paper published in Annals of Internal Medicine this week has hit the international headlines as it shows that 1 out of 3 breast cancer patients are treated unnecessarily. Chief medical officer at the American Cancer Society says it's time to rethink mammography.
In an Op-Ed published in the Norwegian daily newspaper Dagens Næringsliv (DN) on November 29, researchers from the Clinical Effectiveness Research group criticize Norwegian private hospital Aleris' offer to women for mammography screening. Aleris actively offers mammography to women outside the recommended screening age and with shorter intervals, a service which is associated with more harm than benefit. The authors suspect Aleris of creating health anxiety in order to maximize profit.
There are ongoing discussions about whether to implement a national screening program for colorectal cancer in Norway. Prof. Bretthauer has contributed in a summary of the current evidence base regarding health effects of this type of screening. A decision is expected this fall.
This week's issue of the Journal of the Norwegian Medical Association is presenting a portrait interview of Mette Kalager, leader of the Clinical Effectiveness Group. Kalager reveals insights about early career struggles, recent acknowledgements and aims for the future.
The Clinical Effectiveness Group is in the final round to be awarded status as a new Norwegian Centre of Excellence (SFF) 2016. In the event of an SFF-award the group will start up the Norwegian Institute of Cancer screening Evidence and Research (NICER). Watch the film about NICER!
The Clinical Effectiveness group has recently published an article in the journal «Gut» about the challenges in estimating risk of colorectal cancer among patients with IBD, and proposals on how to solve them.
The Clinical Effectiveness Research Group at the University of Oslo is publishing papers on clinical trials and observational research in leading medical journals. Topics of publication include cancer screening, with particular emphasis on breast cancer and colorectal cancer, endoscopy and epidemiologic methodology.
Mette Kalager publishes an article on concerns about data sharing in The New England Journal of Medicine. In the article, Kalager proposes solutions on how to make data sharing a success.
The first ever randomised controlled trial on colorectal cancer (CRC) screening with colonoscopy reveals significant differences between endoscopists' performances. Findings from the NordICC-study was published this week in JAMA Internal Medicine.
Despite compelling evidence for using carbon dioxide (CO2) to reduce patient pain after colonoscopy, most endoscopists worldwide still use air insufflation during colonoscopy. A new paper aims to encourage change and new standards.
The leading scientific journal «Endoscopy» has today released the first paper from the European Polyp Surveillance (EPoS) study group.
Professor Michael Bretthauer is awarded FRIPRO Toppforsk 2016. FRIPRO is a joint initiative between the research institutions and the Norwegian Research Council, with the purpose of supporting groups in the forefront of international research.
The University Hospital of North Norway (UNN) and the University of Tromsø (UiT) are now participants in what is described as the world's largest research project on bowel cancer EPoS according to the newspaper iTromsø.
A large portrait interview with Michael Bretthauer reveals insights about his early career in Norway, and how he had to perform a colonoscopy on a world-renowned medical researcher to convince him to join a large study on colonoscopy.
Endoscopic screening for gastrointestinal cancers has been introduced in many countries. Precise estimates of the magnitude of benefits and harms of endoscopic screening for cancer are a prerequisite for informed decision making for or against participation in screening for individuals in the target population.
After one year with preparations, the EPoS (European Polyp Surveillance Trial) trial has started patient recruitment. The EPoS study will include 30,000 patients over the next three years. Aim of the study is to find better surveillance intervals for patients with colorectal polyps.
The Clinical Effectiveness Research Group recently held a course in Medical Publishing hosted by the University of Bari in Italy. The course was a great success and the participants were satisfied with both the execution and the content of the course.
In the past years we have had a heated debate on the benefits and harms of mammography screening. In this review, the authors discuss the benefits and harms in light of findings from randomized trials, and from more recent observational studies performed in the era of modern diagnostics and treatment.
This review outlines the most current thinking regarding the effectiveness of colonoscopy as a screening tool. It also outlines key concepts to optimize its performance through robust quality assurance programmes and high-quality training. The review is published in GUT.